Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
VEGFR TKI
Tivozanib
Fotivda · Tivo
A highly selective VEGFR inhibitor for refractory RCC, with hypertension as its hallmark on-target toxicity.
ModerateSelective VEGFR inhibitor · approved 2021
Relapsed or refractory advanced renal cell carcinoma
Signature kidney injury
Hypertension
Representative incidence20%
In the phase III TIVO-3 trial, hypertension was the most common grade 3-4 treatment-related adverse event, occurring in about 20% of tivozanib-treated patients; proteinuria occurs as a VEGFR class effect but is comparatively less prominent.
Source: Rini et al., Lancet Oncol 2020 (TIVO-3, grade 3-4 hypertension)
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
0%incidence
SeverityModerate
ReversibilityReversible
Evidence0 refs
Nephron map
GlomerulusFiltration barrier (podocytes + endothelium)
Vasculature / EndotheliumGlomerular & peritubular capillaries
Hypertension
On-target loss of endothelial nitric oxide from VEGF-pathway blockade — so consistent it marks drug activity.
Mechanism of kidney injury
Highly selective VEGFR tyrosine kinase inhibition reduces glomerular VEGF and nitric-oxide signaling, raising vascular tone (the dominant on-target hypertension) and potentially injuring the glomerular filtration barrier (proteinuria); the TKI class can produce an FSGS/MCD-pattern podocytopathy. Because off-target kinase inhibition is minimal, hypertension predominates over other toxicities.
Clinical presentation
New or worsening hypertension, sometimes with proteinuria; creatinine may rise in more severe or volume-depleted cases.
Onset
Within the first weeks of therapy.
Reversibility
Reversible
Anticancer mechanism
Potent, highly selective inhibitor of VEGFR1-3 with a long half-life, suppressing tumor angiogenesis with relatively few off-target kinase effects (which contributes to a comparatively clean non-renal toxicity profile). Approved for relapsed or refractory advanced renal cell carcinoma after two or more prior systemic therapies.
Management
Antihypertensive therapy (ACE inhibitor/ARB favored); interrupt or dose-reduce per label for grade 3 hypertension or significant proteinuria; discontinue for nephrotic syndrome or hypertensive crisis. Effects generally improve with dose modification or withdrawal.
Risk factors
- Pre-existing hypertension
- Baseline proteinuria or CKD
Prevention
- Baseline and periodic blood pressure and urine protein monitoring
- Blood pressure optimization before and during therapy
Note · High VEGFR selectivity makes hypertension the dominant on-target renal-vascular toxicity; proteinuria data are more limited than for less-selective TKIs such as lenvatinib and cabozantinib.
Clinical depth
Renal dose adjustment
No dose adjustment for mild-to-moderate renal impairment; tivozanib has not been studied in severe renal impairment, and it is primarily hepatically metabolized, so renal dosing rules are minimal. Monitor closely if used in advanced CKD.
Dialyzability & ESKD dosing
Highly protein-bound with a long half-life and hepatic clearance; not appreciably dialyzable and not adjusted for HD. Data in dialysis patients are sparse.
Differential diagnosis
On-target VEGFR-TKI hypertension (and less commonly proteinuria/podocytopathy) versus baseline hypertensive/diabetic nephropathy and prerenal AKI. In RCC, also account for reduced renal mass from prior nephrectomy when interpreting creatinine.
Monitoring
- Blood pressure regularly, especially in the first 1-2 months
- Urine protein (dipstick/UPCR) before each cycle
- Serum creatinine periodically
Key trials & series
- TIVO-3 phase III trial (tivozanib vs sorafenib in heavily pretreated metastatic RCC) — hypertension the leading grade 3-4 AE
- TIVO-1 (first-line RCC) — earlier hypertension safety signal
Clinical pearls
- Tivozanib's selectivity makes hypertension its signature toxicity, with fewer competing off-target effects.
- Anticipate hypertension early and pretreat/optimize BP, as it is the most common grade 3-4 event.
- Proteinuria is less prominent than with lenvatinib/cabozantinib but should still be tracked.
Where it strikes
Nephron segments
Glomerulus
Filtration barrier (podocytes + endothelium)
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
HypertensionGlomerular Injury / Proteinuria
Beyond the kidney
Class-level context for the major non-renal toxicities of vegfr tkis.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Hypertension, arterial/venous thrombosis, bleeding, impaired wound healing
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- LV dysfunction; QT (some TKIs)
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea, perforation/fistula
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Hand-foot skin reaction
Evidence
5 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkTivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.Rini BI et al. · Lancet Oncol 2020 · PMID 31810797Pivotal trial: hypertension the most common grade 3-4 event (~20%) with tivozanib.PMIDTherapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.Estrada CC et al. · J Am Soc Nephrol 2019 · PMID 30642877Mechanistic basis of VEGFR-TKI hypertension and glomerular proteinuria.PMIDThe Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread".Sanidas E et al. · Am J Hypertens 2018 · PMID 29788148Reviews mechanisms and management of antiangiogenic hypertension.PMIDProteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.Tesarova P et al. · Folia Biol (Praha) 2013 · PMID 23537524Class review of anti-VEGF proteinuria and hypertension.PMIDNephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update.Nervo A et al. · Crit Rev Oncol Hematol 2021 · PMID 34801702Comparative renal-AE context across VEGFR-TKIs including more- and less-selective agents.
Related agents
Other agents sharing the same signature kidney injury.